Epygenix Therapeutics has been acquired by Harmony Biosciences, a pharmaceutical company dedicated to developing and commercializing
innovative therapies for patients with rare neurological diseases. For more information on Harmony and the acquisition, please click here
The Argus Trial is continuing uninterrupted with Harmony Biosciences.
Living with Dravet Syndrome
First Name
Who We Are
A Better Tomorrow for People Living with Rare Genetic Epilepsies
Epygenix is a clinical stage biopharmaceutical company focused on developing treatments for rare and intractable genetic epilepsies. Powered by a first-of-its-kind, highly predictive, genetic screening platform that validates treatment responsiveness, our multi-asset pipeline of preclinically validated drug candidates targets Dravet syndrome (DS), Lennox-Gastaut syndrome (LGS), and other forms of genetic epilepsies.
While there are multiple antiepileptic drugs available, to date none provide the complete efficacy, safety and ease of administration sought by the epilepsy community. There remains a high unmet need for treatment alternatives and we are passionate about changing the way epileptic drugs are discovered and developed.
Today the Epygenix team has accomplished preclinical development, IND-enabling studies, and Orphan Drug and Rare Pediatric Disease Designations with the EPX portfolio of drug candidates.
1. Aenean sit amet arcu laoreet
Suspendisse lobortis fermentum tellus, et dictum enim lobortis vel. Pellentesque elementum volutpat lacus, at egestas nunc sollicitudin sed. Proin eu dui a enim feugiat ullamcorper ac non est.
2. Aenean sit amet arcu laoreet
Suspendisse lobortis fermentum tellus, et dictum enim lobortis vel. Pellentesque elementum volutpat lacus, at egestas nunc sollicitudin sed. Proin eu dui a enim feugiat ullamcorper ac non est.
3. Aenean sit amet arcu laoreet
Suspendisse lobortis fermentum tellus, et dictum enim lobortis vel. Pellentesque elementum volutpat lacus, at egestas nunc sollicitudin sed. Proin eu dui a enim feugiat ullamcorper ac non est.
Curabitur eu eros non est lacinia ornare at at purus. Praesent sed convallis massa, non finibus neque. Vestibulum ante ipsum primis in faucibus orci luctus et ultrices posuere cubilia curae; Donec nec facilisis ligula. Mauris tincidunt ex quis elit tincidunt, at mattis ligula condimentum. Fusce lacinia eleifend sapien quis dapibus. Donec condimentum mi quis justo convallis, at venenatis erat rhoncus.
Suspendi ultrice
​
Vestibulum ante ipsum primis in faucibus orci luctus et ultrices posuere cubilia curae; Donec nec facilisis ligula. Mauris tincidunt ex quis elit tincidunt.
Suspendi ultrice
​
Vestibulum ante ipsum primis in faucibus orci luctus et ultrices posuere cubilia curae; Donec nec facilisis ligula. Mauris tincidunt ex quis elit tincidunt.
Suspendi ultrice
​
Vestibulum ante ipsum primis in faucibus orci luctus et ultrices posuere cubilia curae; Donec nec facilisis ligula. Mauris tincidunt ex quis elit tincidunt.
Alex Yang, J.D., L.L.M.
Chief and Executive Director of the Board
Alex Yang, J.D., L.L.M. is the original funder of Epygenix Therapeutics, Inc. and the CEO/owner of Mstone Partners which serves as the major shareholder of Epygenix Therapeutics Inc. Alex also serves as the CEO of Curyx Partners, a biotech incubation platform which has set up a number of drug development companies in both pre-clinical and clinical stages.
​
Alex has over 25 years of experience in advising and executing fund formation, cross-border transactions and a diverse pool of investment experiences in multiple industry sectors. He currently serves investment and risk committee member roles for various regional and country-focused private equity funds. Alex is formerly a managing partner at Kim & Chang and was a partner at the Ernst & Young Hong Kong office leading regional financial services practice, including banking and capital markets, asset management and insurance.
Alex formerly worked at the Morgan Stanley Hong Kong Office in the capacity of its Asia Private Equity and In-house Counsel, focused on buy-outs and grow-capital investments, real estate, special situation and infrastructure transactions across Asia. He also worked at Coopers & Lybrand and Ernst & Young New York offices in their international tax and consulting divisions.
​
Alex graduated from New York University School of Law with both J.D. and L.L.M. degrees and a bar with the State of New York and received an undergraduate degree from Binghamton University with Economics.
Hahn-Jun Lee, M.Sc., Ph.D.
Executive Director of the Board
Hahn-Jun Lee, M.Sc., Ph.D. is a serial entrepreneur who founded Epygenix Therapeutics, Inc. which develops precision medicines for rare and intractable pediatric genetic epilepsies. He also founded Polaryx Therapeutics, Inc which develops patient-friendly medicines for lysosomal storage disorders and Focus Therapeutics, L.L.C., a business catalyst in the biotech-pharma industry. He also co-founded Curyx Partners, LLC, a drug development platform.
He has extensive experiences in R&D, deal making, business development, and consulting several top-notch health care venture capital firms and global pharma and biotech companies, including Doman Associates, Shire Human Genetic Therapies, P&G Pharma, Melior Discovery, CDI, etc. He also consulted with several Korean biotechs, venture capital firms, and research institutes.
Dr. Lee was an Assistant Professor of Biotechnology in the Department of Orthopedic Surgery, College of Physicians and Surgeons, Columbia University in the City of New York. He also worked as a Staff Scientist at the RIKEN Brain Science Institute in Japan.
He obtained a B.S. in Life Science from Sogang University, Seoul, Korea. He completed his M.S. and Ph.D. in applied biotechnology in the Department of Applied Biotechnology at the University of Tokyo, Japan.
Mary Shatzoff, M.Sc., RAC
Head of Regulatory Affairs
Mary Shatzoff, M.Sc., RAC, has over 25 years of experience in regulatory affairs in the pharmaceutical industry in clinical drug development. She is currently on the faculty at Wake Forrest School of Medicine as an Adjunct Professor of Regulatory Affairs. She also worked at Sanofi Aventis and Pfizer and as an independent consultant for several companies.
She has contributed to over 100 drug and biologic product applications and led and participated in development and marketing approval of products with therapeutic areas: Anti-Infective, Gastroenterology, Dermatology, Urology, and Neurology. She has extensive experience with regulatory bodies such as the FDA (CDER, CBER, and OOPD), EMA, Health Canada, and TGA.
She has a Regulatory Affairs Certification (RAC-US) and is a Certified Quality Auditor (CQA).
Andrew O
Head of Investor Relations and Business Development Director
Andrew O is a seasoned investor and executive with over 25 years of financial, investment, investor relations, and management expertise at top financial institutions.
​
Andrew was most recently Senior Portfolio Manager and Managing Director at Manulife Investment Management. At Manulife, Andrew was portfolio manager for the Asia Pacific Ex-Japan Small Cap Fund and Korea Specialist Portfolio Manager for larger regional mandates. Among his principal roles was marketing to and communicating with institutional investors. He had full investment discretion and responsibility for portfolio construction; single stock fundamental analysis; position sizing; monitoring and liquidation; sector and country allocation management; specialist team management; P&L; risk and volatility management.
Earlier, he served has Managing Director at Horizon Asset International as a Portfolio Manager running an Asia-Ex Japan Long-Short fundamental book, Executive Director and Head of Research at FrontPoint Partners (Morgan Stanley Investment Management subsidiary) for the Asia-Ex-Japan Long-Short fundamental package, and Executive Director at Goldman Sachs in the Equities Division. Before that, Andrew served as Assistant Investment Officer in the Asia Financial Markets group at the International Finance Corporation, the World Bank’s private investment arm.
​
Andrew received his Bachelors from the University of Pennsylvania and undertook Master’s level studies at Yonsei University’s Graduate School of International Studies.
Anthony Lam, CFA, CPA
Head of Strategic Development
Anthony Lam has over 20 years of experience in private equity investing. He was Chief Investment Officer of Transpac Capital Limited, one of the earliest pan-Asian venture capital/private equity platforms in the region. Before joining Transpac, Mr. Lam was one of the founding Managing Directors and Head of China at Asia Climate Partners, the largest climate related private equity fund in the region. Prior to Asia Climate Partners, he was Managing Director and Co-Head Asia Pacific of TRG Management, The Rohatyn Group. Mr. Lam served on the global investment committee and managed a portfolio of seven investee companies with a total investment amount of over $600 million in China, Singapore, South Korea as well as Thailand. Prior to joining TRG, Mr. Lam was a partner at Citigroup Venture Capital International, the private equity arm of Citigroup, with cumulative AUM over US $6 billion. During his tenure at Citigroup, Mr. Lam had led or actively participated in private equity transactions in a variety of industries including healthcare, renewable energy, financial, consumer, retail, telecommunication, industrial, and technology. Mr. Lam received his M.B.A. from the Chinese University of Hong Kong and is a Chartered Financial Analyst and Certified Public Accountant-Inactive.